Browsing by Author "Uysal, Mukremin"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Article
    Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients With Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study
    (Taylor & Francis Inc, 2025) Uysal, Mukremin; Saglam, Sezer; Beypinar, Ismail; Saglam, Esra Kaytan; Mammadov, Elkhan; Ocak, Birol; Karabulut, Bulent
    The goal of this study was to look at the long-term survival outcomes and clinical characteristics of stage II/III locally advanced rectal cancer (LARC) patients who acquired pathological complete response (pCR) following neoadjuvant chemoradiotherapy (NCRT). The clinicopathological characteristics and treatment details of 277 LARC patients with pCR, relapse-free survival (RFS), overall survival (OS), and locoregional and systemic recurrence rates, were assessed. The 5-year RFS and OS rates were 85.6% and 90.9%. The rates of local and systemic recurrence were 3.6% and 7.9%. Our study confirmed the favorable results in survival in patients with LARC who achieved pCR
  • Thumbnail Image
    Article
    Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 Metastatic Breast Cancer Patients: a Turkish Oncology Group (Tog) Study
    (Taylor & Francis inc, 2022) Bilici, Ahmet; Uysal, Mukremin; Menekse, Serkan; Akin, Semih; Yildiz, Fatih; Turan, Merve; Turhal, Serdar
    Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.